MAKO Surgical Corp. Announces Additions to Senior Management Team
March 29 2010 - 4:05PM
MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that
markets both its RIO® robotic arm interactive orthopedic surgical
platform and proprietary RESTORIS® implants for minimally invasive
orthopedic knee procedures known as MAKOplasty®, today announced
that Richard Leparmentier has been appointed to the newly created
position of Senior Vice President of Engineering, assuming
responsibility for MAKO's research and development activities,
which were formerly overseen by Rony Abovitz. Mr. Abovitz will
remain the Chief Visionary Officer and Co-Founder of the Company.
MAKO also announced the appointment of James E. Keller to the
Company's newly created position of Senior Vice President of
Regulatory Affairs and Quality Assurance. Mr. Leparmentier,
Mr. Abovitz and Mr. Keller will report to Maurice R. Ferre, M.D.,
MAKO's President and Chief Executive Officer.
"As MAKO positions itself for future growth, we are fortunate to
have gained the benefit of Richard's significant leadership
experience, while having maintained the advantage of Rony's
visionary and strategic talents which have significantly
contributed to our success to date," said Dr.
Ferre. "Moreover, the addition of Jim Keller further advances
MAKO's efforts to build a world class management team to
effectively plan for and manage our expected future growth."
From 2007 to 2010, Mr. Leparmentier served as U.S. VP of Design
and Engineering for ASML, a Dutch lithography equipment company.
From 1995 to 2006, Mr. Leparmentier held various positions with GE
Healthcare, including Vice President of OEC-Surgery Engineering, a
leader in surgical x-ray and navigation equipment, Engineering
Manager for radiography products in China, and Lead System Designer
for radiographic products in Buc, France. Mr. Leparmentier
holds an Engineering Degree in Biology and Micromechanics from
Ecole Politechnique in France.
From 2008 to 2009, Mr. Keller served as VP of Regulatory Affairs
& Pharmacovigilence for Medicis Pharmaceutical Corp., a mid-cap
diversified drug and Class 3 medical device company for the
aesthetic and dermatology markets. From 2007 to 2008, Mr. Keller
served as Vice President of Regulatory Affairs & Quality
Assurance for F. Dohmen Company, a small healthcare services
company. From 2005 to 2007, Mr. Keller served as the Vice President
of Clinical, Spinal & Biologics for the orthopedic and
biologics division of Medtronic, a large medical device
company. From 2001 to 2005, Mr. Keller served as Vice
President of Regulatory Affairs & Quality Assurance for Light
Sciences Corporation, an early-stage biotechnology development
company. From 1996 to 2000, Mr. Keller served as Vice
President of Regulatory Affairs for Mallinckrodt, a pharmaceutical
and medical device company. Beginning in 1987, Mr. Keller held
various positions with E.I. Du Pont de Nemours, including Associate
Director of Regulatory Affairs with DuPont Pharmaceuticals and
Manager of Regulatory Affairs, Quality Assurance and Government
Affairs with DuPont Medical Products. Mr. Keller holds a B.S. in
Microbiology from Clemson University and an M.B.A. from John M.
Olin School of Business, Washington University.
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets
both its RIO® Robotic-Arm Interactive Orthopedic system and its
proprietary RESTORIS® implants for minimally invasive orthopedic
knee procedures. The MAKO RIO is a surgeon-interactive tactile
surgical platform that incorporates a robotic arm and
patient-specific visualization technology and prepares the knee
joint for the insertion and alignment of MAKO's resurfacing
RESTORIS implants through a minimal incision. The FDA-cleared RIO
system allows surgeons to provide a precise, consistently
reproducible tissue-sparing, bone resurfacing procedure called
MAKOplasty® to a large, yet underserved patient population
suffering from early to mid-stage osteoarthritic knee disease. MAKO
has an intellectual property portfolio of more than 250 licensed or
owned patents and patent applications relating to the areas of
robotics, haptics, computer assisted surgery and implants.
Additional information can be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing" or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability
to control or predict. Such factors, among others, may have a
material adverse effect on MAKO's business, financial condition and
results of operations and may include the potentially significant
impact of a continued economic downturn or delayed economic
recovery on the ability of MAKO's customers to secure adequate
funding to buy MAKO's products or cause MAKO's customers to delay a
purchasing decision, changes in competitive conditions and prices
in MAKO's markets, unanticipated issues relating to intended
product launches, decreases in sales of MAKO's principal product
lines, increases in expenditures related to increased or changing
governmental regulation or taxation of MAKO's business,
unanticipated issues in securing regulatory clearance or approvals
for new products or upgrades or changes to MAKO's products,
unanticipated issues associated with any healthcare reform
legislation that may be enacted, loss of key management and other
personnel or inability to attract such management and other
personnel and unanticipated intellectual property expenditures
required to develop, market, and defend MAKO's products. These and
other risks are described in greater detail under Item 1A, "Risk
Factors," in MAKO's annual report on Form 10-K for the year ended
December 31, 2009 filed with the Securities and Exchange Commission
on March 10, 2010. Given these uncertainties, undue reliance should
not be placed on these forward-looking statements. MAKO does not
undertake any obligation to release any revisions to these
forward-looking statements publicly to reflect events or
circumstances after the date of this press release or to reflect
the occurrence of unanticipated events.
"MAKOplasty®," "RESTORIS®," "RIO®," "Tactile Guidance System™"
and "TGS™," as well as the "MAKO" logo, whether standing alone or
in connection with the words "MAKO Surgical Corp." are trademarks
of MAKO Surgical Corp.
CONTACT: MAKO Surgical Corp.
Investors:
Susan M. Verde
954-927-2044 x349
sverde@makosurgical.com
Westwicke Partners
Mark Klausner
410-321-9650
mark.klausner@westwickepartners.com
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024